-+ 0.00%
-+ 0.00%
-+ 0.00%

Klaria Pharma issues corrected version of Q2 2026 interim report

PUBT·09/01/2026 06:35:11
Listen to the news
Klaria Pharma issues corrected version of Q2 2026 interim report
  • Klaria issued a corrected version of its Q2 2026 interim report, replacing the previously published report.
  • The updated report still showed zero Q2 revenue, a net loss of SEK 12.9 million, operating cash outflow of SEK 14.8 million.
  • Cash at June 30 was SEK 8.5 million. Group equity was negative at SEK 33.6 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Klaria Pharma Holding AB published the original content used to generate this news brief via Cision (Ref. ID: 202609010234BITN____UKPR__SV_20260901-BIT-4639-0) on September 01, 2026, and is solely responsible for the information contained therein.